Home » Stocks » NVAX

Novavax, Inc. (NVAX)

Stock Price: $121.37 USD -6.45 (-5.05%)
Updated May 13, 2021 2:13 PM EDT - Market open
Market Cap 9.48B
Revenue (ttm) 919.45M
Net Income (ttm) -615.11M
Shares Out 73.04M
EPS (ttm) -7.27
PE Ratio n/a
Forward PE 39.06
Dividend n/a
Dividend Yield n/a
Trading Day May 13
Last Price $121.37
Previous Close $127.82
Change ($) -6.45
Change (%) -5.05%
Day's Open 129.40
Day's Range 117.12 - 133.44
Day's Volume 3,929,783
52-Week Range 37.37 - 331.68

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

If Novavax is successful, it could generate billions.

8 hours ago - The Motley Fool

Human trials of the combination vaccine are expected to start later this year.

1 day ago - The Motley Fool

Novavax Vaccine in 'Good Shape' for Approval Filing: CEO

YouTube video

May.12 -- Novavax Inc. CEO Stan Erck says manufacturing challenges are behind the delay in the company's plan to file for authorization of its Covid-19. He speaks on "Bloomberg Markets: European Close.

1 day ago - Bloomberg Markets and Finance

Novavax, Inc. (NASDAQ:NVAX) shares are trading lower by 3.7% at $133.05 after JPMorgan downgraded the stock from Overweight to Neutral and lowered its price target from $285 to $161 per share. Novavax i...

1 day ago - Benzinga

The stock price of Novavax has seen a large 18% drop in just five trading sessions. The decline was driven partly due to the company's announcement that it doesn't plan to file for authorization for its...

1 day ago - Forbes

The European Commission president has provided some hints that a supply agreement with Novavax could be on the way.

Other stocks mentioned: BNTX, MRNA, PFE
1 day ago - The Motley Fool

An analyst's price target cut reflected an uncomfortable new reality for the biotech.

1 day ago - The Motley Fool

Novavax (NVAX) reports wider-than-expected loss in the first quarter of 2021 while revenues beat estimates. Shares fall in after-hours trading.

2 days ago - Zacks Investment Research

The patent waiver matter will likely prove to be a "nonissue," while NVAX stock has many upcoming, positive catalysts. The post Ahead of Positive Catalysts, Novavax Stock Is Attractive on Weakness appea...

2 days ago - InvestorPlace

Novavax Inc (NASDAQ: NVAX) delayed ramping up COVID-19 vaccine production again on Monday and said it was unlikely to seek regulatory approval for its shot in Europe, UK, and the United States until Q3 ...

2 days ago - Invezz

The Covid-19 treatment response process includes a number of different major players, including Pfizer Inc (NYSE: PFE), BioNTech SE – ADR (NASDAQ: BNTX), Moderna Inc (NASDAQ: MRNA), AstraZeneca plc (NAS...

Other stocks mentioned: HALB, MRNA
2 days ago - OTC PR Wire

Vaccine stocks had a rough week, with Novavax stock down almost -25%, Moderna down by about -9%, and Pfizer stock up by just about 2% despite posting a very solid set of first-quarter results. The decli...

Other stocks mentioned: MRNA
2 days ago - Forbes

The government is having issues with giving away its excess supply.

Other stocks mentioned: AZN, BNTX, JNJ, MRNA, PFE
2 days ago - The Motley Fool

It had nothing to do with the company's financial performance.

2 days ago - The Motley Fool

Novavax, Inc (NASDAQ: NVAX) shares fell over 12% in the after-hours trading on Monday after closing almost 8.8% lower in regular trading. What Happened: The after-hours dip came as the Maryland-based co...

2 days ago - Benzinga

In the latest trading session, Novavax (NVAX) closed at $160.50, marking a -8.81% move from the previous day.

2 days ago - Zacks Investment Research

Novavax (NVAX) delivered earnings and revenue surprises of -15.09% and 53.23%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?

2 days ago - Zacks Investment Research

The company's latest coronavirus vaccine news produced an unpleasant side effect.

2 days ago - The Motley Fool

Novavax Inc said on Monday it will ramp up production of its COVID-19 vaccine slower than it had previously anticipated and does not expect to file for regulatory approval in the United States, Britain ...

2 days ago - Reuters

Shares of Novavax (NASDAQ:NVAX) rose after the company reported Q1 results. Quarterly Results Earnings per share were down 425.86% over the past year to ($3.05), which beat the estimate of ($3.60).

2 days ago - Benzinga

GAITHERSBURG, Md., May 10, 2021 /PRNewswire/ -- Novavax, Inc. (NASDAQ: NVAX), a biotechnology company developing next-generation vaccines for serious infectious diseases, today announced its financial r...

2 days ago - PRNewsWire

A big capital gains tax is looming, threatening to trigger a selloff on companies whose stock ran up the most. The post 7 Stocks Most at Risk of a Capital Gains Tax Selloff  appeared first on InvestorPl...

Other stocks mentioned: AMZN, GME, MSTR, NIO, SI, TSLA
3 days ago - InvestorPlace

Novavax, Inc. (NVAX) announced positive results from the animal study of its combo vaccine for influenza and COVID-19. The positive news however did little to stem the sell-off in shares that began in l...

3 days ago - Benzinga

Novavax (NASDAQ: NVAX) shares are trading lower amid reports competing COVID-19 vaccines may be approved in Europe. The stock also dipped on reports the company is unlikely to seek emergency use authori...

3 days ago - Benzinga

- Manuscript highlights development of robust responses to both influenza and COVID-19 and protection against the SARS-CoV-2 virus - Data shared via preprint server for biology, bioRxiv, ahead of public...

3 days ago - PRNewsWire

Final Trades: American Tower, Novavax, Small caps & more

YouTube video

The "Halftime Report" traders give their top picks to watch for the second half.

Other stocks mentioned: AMT, MRNA, SVAL
6 days ago - CNBC Television

The danger is overstated.

6 days ago - The Motley Fool

Oppenheimer health care analyst on whether vaccine makers should lose sleep over patent waivers

YouTube video

Hartaj Singh, Oppenheimer & Co, on Covid vaccine makers under pressure as the patent waiver conversation continues. With CNBC's Melissa Lee and the Fast Money traders, Guy Adami, Pete Najarian, Jeff Mil...

Other stocks mentioned: AZN, BNTX, JNJ, MRNA, PFE
6 days ago - CNBC Television

Pfizer fell Thursday by as much as 5% from Wednesday's close while Moderna dipped by almost 12% before both stocks recovered most of those losses.

Other stocks mentioned: BNTX, JNJ, MRNA, PFE
6 days ago - CNBC

U.S. backs COVID-19 vaccine patent waiver

YouTube video

Yahoo Finance's Brian Sozzi, Myles Udland, Julie Hyman, and Anjalee Khemlani discuss what the vaccine patent waiver means for Moderna's business.

Other stocks mentioned: BNTX, JNJ, MRNA, PFE
1 week ago - Yahoo Finance

Moderna, Inc. (NASDAQ: MRNA). uniQure N.V.

Other stocks mentioned: MRNA, QURE
1 week ago - Benzinga

Novavax to deliver 350 million doses beginning Q3 2021 1.1 billion doses of Novavax vaccine to be available to countries participating in COVAX Serum Institute of India to provide balance of doses for L...

1 week ago - PRNewsWire

If enacted, such a move would hit the smaller vaccine makers particularly hard.

Other stocks mentioned: BNTX, JNJ, MRNA, PFE
1 week ago - The Motley Fool

Vaccine makers sink as Biden considers waving patents

YouTube video

Brent Saunders, former Allergan CEO, on who will make the vaccine next time. With CNBC's Melissa Lee and the Fast Money traders, Tim Seymour, Karen Finerman, Dan Nathan and Nadine Terman.

Other stocks mentioned: BNTX, MRNA, PFE, JNJ
1 week ago - CNBC Television

GAITHERSBURG, Md., May 5, 2021 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a biotechnology company developing next-generation vaccines for serious infectious diseases, today announced the publication ...

1 week ago - PRNewsWire

It may offer key COVID program updates.

1 week ago - The Motley Fool

Let's take a look at some top coronavirus vaccine stories of April and the possible impact they can have on biotech ETFs.

Other stocks mentioned: AZN, BBH, BTEC, FBT, IBB, IBRX, JNJ ...
1 week ago - Zacks Investment Research

Showered with optimism in April, shareholders will have to wait for the bloom.

1 week ago - The Motley Fool

Berkshire Hathaway, Pfizer, Novavax and Amazon were our top stock trades for Tuesday. Now, let's get a look at the charts as we kickoff May.

Other stocks mentioned: AMZN, BRK.A, BRK.B, PFE
1 week ago - InvestorPlace

Shares of coronavirus vaccine developer Novavax, Inc. (NASDAQ: NVAX) were moving sharply to the downside on above-average volume Monday. The move comes despite the company announcing that it has added a...

1 week ago - Benzinga

Find out what was responsible for the Nasdaq missing out on gains.

Other stocks mentioned: TSLA
1 week ago - The Motley Fool

NVAX stock is losing today, even with two big announcements this morning. Speculators seem to think these announcements will lead to delays.

1 week ago - InvestorPlace

Novavax Inc (NASDAQ: NVAX) has told the European Union it plans to begin delivering its COVID-19 vaccine to the bloc towards the end of this year, A formal contract could be signed as early as this week...

1 week ago - Benzinga

Investors don't like the timing of a potential supply deal with the EU.

1 week ago - The Motley Fool

Novavax Inc (NASDAQ: NVAX) has initiated a pediatric expansion of its Phase 3 PREVENT-19 trial for NVX-CoV2373, its COVID-19 vaccine candidate. The additional arm of the ongoing PREVENT-19 pivotal trial...

1 week ago - Benzinga

GAITHERSBURG, Md., May 3, 2021 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a biotechnology company developing next-generation vaccines for serious infectious diseases, today announced that it has init...

1 week ago - PRNewsWire

In the latest trading session, Novavax (NVAX) closed at $236.93, marking a -0.25% move from the previous day.

1 week ago - Zacks Investment Research

According to an SEC filing, Novavax Inc (NASDAQ: NVAX) has received an additional $147.3M as part of Operation Warp Speed to develop a COVID-19 vaccine dubbed NVX-CoV2373. This addition brings its total...

1 week ago - Benzinga

The stocks of Novavax and Axsome Therapeutics are soaring. Here's why.

Other stocks mentioned: AXSM
1 week ago - The Motley Fool

Novavax (NVAX) is reportedly set to receive the fourth authorization for COVID-19 vaccine in the United States.

2 weeks ago - Zacks Investment Research

About NVAX

Novavax, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of vaccines to prevent serious infectious diseases and address health needs. The company's vaccine candidates include NVX-CoV2373, a coronavirus vaccine candidate that is in two Phase III trials, one Phase IIb trial, and one Phase I/II trial; NanoFlu, a nanoparticle seasonal quadrivalent influenza vaccine candidate that is in Phase 3 clinical trial; and ResVax, a respiratory syncytial virus (RSV) fusion (F) protein nanoparticle vaccine candidate... [Read more...]

Industry
Biotechnology
IPO Date
Dec 5, 1995
CEO
Stanley Erck
Employees
792
Stock Exchange
NASDAQ
Ticker Symbol
NVAX
Full Company Profile

Financial Performance

In 2020, Novavax's revenue was $475.60 million, an increase of 2,448.48% compared to the previous year's $18.66 million. Losses were -$418.26 million, 215.2% more than in 2019.

Financial Statements

Analyst Forecasts

According to 7 analysts, the average rating for Novavax stock is "Buy." The 12-month stock price forecast is 294.00, which is an increase of 142.23% from the latest price.

Price Target
$294.00
(142.23% upside)
Analyst Consensus: Buy